EP0166612A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Potent thymopentin analogs
Assignee: Ortho Pharmaceutical Corp
•
Filing: 1985-06-26
•
Granted: —
•
Expires: 2005-06-26
Abstract
Abstract Immunoregulating peptides are disclosed which are more potent than thymopentin or splenin and are useful for their effects on the immune system, especially the treatment of thymic deficiencies.
Inventors
- 👤 Gideon Goldstein
- 👤 George Heavner
- 👤 Daniel Kroon
- 👤 Tapan Audhya
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 03:52
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/06; C07K14/00; C07K14/435; C07K14/575; C07K14/66; C07K14/662; A; A61; A61P; A61P37/00; A61P37/02; A61P37/04; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/18
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
116 words
A peptide having the formula: R-V-W-X-Y-Z-R 1 or a pharnaceutically-acceptable acid- or base-addition salt thereof, wherein: R is H, loweralkyl, formyl or loweralkanoyl; V is ARG or D-ARG; W is LYS, D-LYS, PRO, dehydro-PRO, or AIB; X is ASP, D-ASP, GLU, or D-GLU; Y is VAL, LYS, LEU, ILE, GLU, ALA, GLN, D-VAL, D-LYS, D- . LEU, D-ILE, D-GLU, D-ALA, or D-GLN; Z is PHE, HIS, TRP, D-PHE, D-HIS, or D-TRP; R 1 is OH or NR 2 R 3 ; and R 2 and R 3 are each independently selected from H or loweralkyl; provided that when W is LYS, X is D-ASP, GLU, or D-GLU, and Y is VAL, Z is other than PHE.
Claim 2
Dependent Claim
116 words
A peptide having the formula: R-V-W-X-Y-Z-R 1 or a pharnaceutically-acceptable acid- or base-addition salt thereof, wherein: R is H, loweralkyl, formyl or loweralkanoyl; V is ARG or D-ARG; W is LYS, D-LYS, PRO, dehydro-PRO, or AIB; X is ASP, D-ASP, GLU, or D-GLU; Y is VAL, LYS, LEU, ILE, GLU, ALA, GLN, D-VAL, D-LYS, D- . LEU, D-ILE, D-GLU, D-ALA, or D-GLN; Z is PHE, HIS, TRP, D-PHE, D-HIS, or D-TRP; R 1 is OH or NR 2 R 3 ; and R 2 and R 3 are each independently selected from H or loweralkyl; provided that when W is LYS, X is D-ASP, GLU, or D-GLU, and Y is VAL, Z is other than PHE.
Claim 3
Dependent Claim
13 words
The peptide of claim 1 wherein Z is PHE, HIS, D-PHE, or D-HIS.
Claim 4
Dependent Claim
23 words
The peptide of claim 1 wherein R is hydrogen or loweralkyl, V is ARG, X is ASP, and Z is PHE or HIS.
Claim 5
Dependent Claim
14 words
The peptide of any one of claims 1 to 3 wherein W is PRO.
Claim 6
Dependent Claim
23 words
A peptide having the formula: α-acetyl-ARG-PRO-ASP-VAL-PHE-OH; d _-formyl-ARG-PRO-ASP-VAL-PHE-OH; α-(loweralkanoyl)-ARG-PRO-ASP-VAL-PHE-OH; H-ARG-PRO-ASP-VAL-PHE-OH; H-ARG-PRO-ASP-VAL-HIS-OH ; H-ARG-LYS-ASP-VAL-HIS-OH; or H-ARG-LYS-ASP-VAL-PHE-OH; or a pharmaceutically-acceptable acid- or base-addition salt thereof.
Claim 7
Dependent Claim
23 words
A peptide having the formula: α-acetyl-ARG-PRO-ASP-VAL-PHE-OH; d _-formyl-ARG-PRO-ASP-VAL-PHE-OH; α-(loweralkanoyl)-ARG-PRO-ASP-VAL-PHE-OH; H-ARG-PRO-ASP-VAL-PHE-OH; H-ARG-PRO-ASP-VAL-HIS-OH ; H-ARG-LYS-ASP-VAL-HIS-OH; or H-ARG-LYS-ASP-VAL-PHE-OH; or a pharmaceutically-acceptable acid- or base-addition salt thereof.
Claim 8
Dependent Claim
31 words
A pharmaceutical composition comprising an effective T cell or B cell inducing amount of a peptide of any one of claims 1 to 5 in admixture with a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
39 words
A peptide of any one of claims 1 to 5 or a composition of claim 6 for treatment of a condition resulting from relative or absolute T cell or B cell deficiency in a subject having such a condition.
Claim 10
Dependent Claim
35 words
A peptide of any one of claims 1 to 5 or a composition of claim 6 for inducing lymphopoietic stem cells of a subject to develop the characteristics of thymus-derived lymphocytes or for inducing precursor
Claim 11
Dependent Claim
13 words
B cells of a subject to develop the characteristics of mature B cells.
Claim 12
Dependent Claim
13 words
B cells of a subject to develop the characteristics of mature B cells.
Claim 13
Dependent Claim
24 words
The use of peptide synthesis techniques to produce a peptide of any one of claims 1 to 5 from its constituent amino acid residues.
Claim 14
Dependent Claim
37 words
A process for producing a composition according to claim 6 comprising admixing an effective T cell or B cell inducing amount of a peptide of any one of claims 1 to 5 with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.